An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiovascular Systems, Inc. (NASDAQ: CSII) will hold a live webcast of its fiscal 2022 Q1 conference call on November 9, 2021, at 8:00 a.m. CT. The call will discuss the financial results for the quarter ending September 30, 2021, along with the company's outlook. An earnings release will precede the call. The company specializes in innovative medical devices for treating vascular disease, particularly through its orbital atherectomy system.
Positive
Upcoming earnings call scheduled for November 9, 2021, may provide insights into financial performance.
Innovative solutions in vascular disease treatment could enhance market position.
Negative
None.
Live Webcast at 8:00 a.m. CT (9:00 a.m. ET)
ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 first-quarter conference call on Tuesday, November 9, 2021, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2021, and its financial outlook. CSI will issue an earnings release prior to the call on November 9, 2021.
To access the live webcast, please register here. A webcast replay will be available later on November 9.
To participate in the conference call, please register here.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.